All Type of News
‘Baraclude’ falls, Lipitor and Viread form two-way strong trend
In the outpatient prescription market, ‘Lipitor(Pfizer)’ and ‘Viread(Gilead Sciences Korea)’ formed the 2-way strong trend.
The BMS Korea’s product which had exclusively led the market for the past years, ‘Baraclude...
“Breixt will bring minor impacts on domestic health industry”
The British withdrawal from the European Union, also known as Brexit, will narrowly impact the domestic healthcare industry, while it might raise competitiveness caused by change of exchange rates instead.
Though the...
Drug store ‘Boots’ enters Korean market, partnering with Emart
The world’s largest drug store company, Walgreeens Boots Alliance(hereinafter referred to Boots), was known to enter the Korean market soon.
Emart announced recent partnership of franchise business with Boots and acq...
Samsung applies Europe approval of ‘SB5,’ third biosimilar
On the 18th, Samsung Bioepis(CEO Han-seung Ko) announced application of the sales approval of the ‘Humira’ biosimilar, ‘SB5,’ to the EMA(European Medicines Agency).
SB5, the Samsung Bioepis’s third biosimilar product...
AstraZeneca encountered the most patent suits related to ‘Brilinta’
While a series of patent suits continues to be filed after the Patent-Linkage System is implemented, AstraZeneca was known to encounter the most number of patent challenges.
According to the analysis result of the M...
Japanese pharmaceutical companies’ sales management expenses increase every year
It was observed Japanese pharmaceutical companies’ average sales and sales management expenses(SME) are growing. When it comes to the characteristic of the domestic market focusing on promotion and marketing activitie...
National Assembly, “Investment performance needs to be improved for global healthcare funds”
The National Assembly pointed out investment performance of pharmaceutical funds managed by the Ministry of Health and Welfare.
The National Assembly Health and Welfare Committee decided the 2015 MOHW Settlement Scre...
Novartis’s rebate investigation extended to professors of endocrinologyThe industry has started to concern that the investigation range of the Novartis Korea’s rebate incident which is limited to a specific field might be extended to the ‘endocrino...
|
“Blind spots of insurance benefits on hepatitis C therapies, Sovaldi & Harvoni, will be resolved”
The hepatitis C treatment, ‘Harvoni(ledipasvir+sofosbuvir),’ will also be applied for the health insurance benefit even if the Dak-Sun combination therapy cannot be used.
Side effects which has been indicated as blin...
‘Xarelto’ registered for prioritized sales right as generic
The novel oral anticoagulant(NOAC), rivaroxaban(product name: Xarelto, Bayer)’ was registered in the list of pharmaceutical products with prioritized sales product approval for the 41th times.
SK Chemicals which suc...
